Search Results - "Coskinas, Xanthi"

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer by Davis, Ian D, Martin, Andrew J, Stockler, Martin R, Begbie, Stephen, Chi, Kim N, Chowdhury, Simon, Coskinas, Xanthi, Frydenberg, Mark, Hague, Wendy E, Horvath, Lisa G, Joshua, Anthony M, Lawrence, Nicola J, Marx, Gavin, McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A, Parnis, Francis, Parulekar, Wendy, Pook, David W, Reaume, M. Neil, Sandhu, Shahneen K, Tan, Alvin, Tan, T. Hsiang, Thomson, Alastair, Tu, Emily, Vera-Badillo, Francisco, Williams, Scott G, Yip, Sonia, Zhang, Alison Y, Zielinski, Robert R, Sweeney, Christopher J

“…In men with metastatic, hormone-sensitive prostate cancer who were receiving testosterone suppression, the addition of enzalutamide led to significantly longer…”
Get full text

Changes to aspects of ongoing randomised controlled trials with fixed designs by Coskinas, Xanthi, Simes, John, Schou, Manjula, Martin, Andrew James

“…Despite careful planning, changes to some aspects of an ongoing randomised clinical trial (RCT), with a fixed design, may be warranted. We sought to elucidate…”
Get full text

Changes to design and analysis elements of research plans during randomised controlled trials in Australia by Coskinas, Xanthi, Simes, R John, Martin, Andrew J

“…Objectives To investigate the frequency and legitimacy of substantive changes to the research plans of published randomised controlled trials (RCTs) undertaken…”
Get full text

Reacting to prognostic covariate imbalance in randomised controlled trials by Coskinas, Xanthi, Schou, I. Manjula, Simes, John, Martin, Andrew

“…Clinical trialists may regard an observed imbalance on a prognostic covariate as sufficiently troubling to warrant action. To elucidate the issues associated…”
Get full text

Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP by Stockler, Martin R, Martin, Andrew J, Davis, Ian D, Dhillon, Haryana M, Begbie, Stephen D, Chi, Kim N, Chowdhury, Simon, Coskinas, Xanthi, Frydenberg, Mark, Hague, Wendy E, Horvath, Lisa G, Joshua, Anthony M, Lawrence, Nicola J, Marx, Gavin M, McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A, Parnis, Francis, Parulekar, Wendy R, Pook, David W, Reaume, M Neil, Sandhu, Shahneen, Tan, Alvin, Tan, Thean Hsiang, Thomson, Alastair, Vera-Badillo, Francisco, Williams, Scott G, Winter, Diana G, Yip, Sonia, Zhang, Alison Y, Zielinski, Robert R, Sweeney, Christopher J

“…We previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we…”
Get full text

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy by Sweeney, Christopher J., Martin, Andrew J., Stockler, Martin R., Begbie, Stephen, Chi, Kim N., Chowdhury, Simon, Coskinas, Xanthi, Frydenberg, Mark, Hague, Wendy E., Horvath, Lisa G., Joshua, Anthony M., Lawrence, Nicola J., Marx, Gavin M., McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A., Parnis, Francis, Parulekar, Wendy, Pook, David W., Reaume, M. Neil, Sandhu, Shahneen K., Tan, Alvin, Tan, Thean Hsiang, Thomson, Alastair, Tu, Emily, Vera-Badillo, Francisco, Williams, Scott G., Yip, Sonia, Zhang, Alison Y., Zielinski, Robert R., Davis, Ian D.

“…Men who initially present with localized prostate cancer and later develop metachronous metastases have a better prognosis than men with de novo metastatic…”
Get full text

Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303) by Williams, Scott, Davis, Ian D., Sweeney, Christopher, Stockler, Martin R., Martin, Andrew James, Hague, Wendy, Coskinas, Xanthi, Yip, Sonia, Tu, Emily, Lawrence, Nicola Jane, McDermott, Ray, Kelly, Paul J., Deignan, Olwyn, Hughes, Simon, Fonteyne, Valerie, Tombal, Bertrand F., Nguyen, Paul L.

“…Abstract only TPS5096 Background: Adjuvant ADT with an LHRH analog (LHRHA) given before, during and after radiotherapy (RT) is standard of care for high risk…”
Get full text

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303) by Williams, Scott, Davis, Ian D., Sweeney, Christopher, Stockler, Martin R., Martin, Andrew James, Hague, Wendy, Coskinas, Xanthi, Yip, Sonia, Tu, Emily, Lawrence, Nicola Jane, Nayar, Namrata, McDermott, Ray, Kelly, Paul, Deignan, Olwyn, Hughes, Simon, Fonteyne, Valerie, Tombal, Bertrand F., Nguyen, Paul L.

“…Abstract only TPS156 Background: Adjuvant ADT with an LHRH analog (LHRHA) given before, during and after radiotherapy (RT) is standard of care for high risk…”
Get full text

Oncologists' estimates of expected survival time and scenarios for survival: accuracy in the ALTG NITRO trial of 1st line chemotherapy for advanced non–small-cell lung cancer by Tognela, Annette, Espinoza, David, Davidson, Andrew, Chan, Matthew MK, Hughes, Brett Gordon Maxwell, Boyer, Michael J., Briscoe, Karen P., Begbie, Stephen, Muljadi, Nick, Coskinas, Xanthi, Pavlakis, Nick, Millward, Michael, Stockler, Martin R., Kiely, Belinda E.

“…Abstract only…”
Get full text

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303) by Williams, Scott G., Davis, Ian D., Sweeney, Christopher, Stockler, Martin R., Martin, Andrew James, Hague, Wendy, Coskinas, Xanthi, Yip, Sonia, Tu, Emily, Chan, Howard, Lawrence, Nicola Jane, McDermott, Ray, Hughes, Simon, Marchesin, Vittorio, Deignan, Olwyn, Nguyen, Paul L.

“…Abstract only…”
Get full text

Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304) by Davis, Ian D., Stockler, Martin R., Martin, Andrew James, Hague, Wendy, Coskinas, Xanthi, Yip, Sonia, Tu, Emily, Lawrence, Nicola Jane, Chan, Howard, McDermott, Ray, Chowdhury, Simon, Marchesin, Vittorio, Deignan, Olwyn, Vera-Badillo, Francisco, North, Scott A., Montenegro, Alexander, Sweeney, Christopher

“…Abstract only…”
Get full text

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303) by Williams, Scott G., Davis, Ian D., Sweeney, Christopher, Stockler, Martin R., Martin, Andrew James, Marchesin, Vittorio, Deignan, Olwyn, McDermott, Ray, Long, Anne Poh, Roncolato, Felicia T, Yip, Sonia, Hague, Wendy, Tu, Emily, Coskinas, Xanthi, Nguyen, Paul Linh

“…Abstract only…”
Get full text

Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304) by Davis, Ian D., Stockler, Martin R., Martin, Andrew James, Marchesin, Vittorio, Deignan, Olwyn, McDermott, Ray, Parulekar, Wendy R., North, Scott A., Graham, Barbara, Long, Anne Poh, Roncolato, Felicia T, Yip, Sonia, Hague, Wendy, Dazo, Carlo, Coskinas, Xanthi, Sweeney, Christopher

“…Abstract only…”
Get full text

Patients' preferences for adjuvant sorafenib after resection of intermediate or high-risk renal cell carcinoma in the SORCE trial: What makes it worthwhile? by Blinman, Prunella Louise, Davis, Ian D., Martin, Andrew, Troon, Simon, Sengupta, Shomik, Hovey, Elizabeth J., Coskinas, Xanthi, Kaplan, Richard S., Ritchie, Alastair W. S., Meade, Angela M., Eisen, Tim, Stockler, Martin R.

“…Abstract only 415 Background: SORCE is an international, double-blind, placebo-controlled, phase 3 trial comparing adjuvant sorafenib for 1 year, for 3 years,…”
Get full text

Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma by Lawrence, Nicola J., Martin, Andrew, Davis, Ian D., Troon, Simon, Sengupta, Shomik, Hovey, Elizabeth, Coskinas, Xanthi, Kaplan, Richard, Smith, Benjamin, Ritchie, Alastair W. S., Meade, Angela, Goh, Jeffrey, Gurney, Howard, Harrison, Michelle, Fife, Kate, Eisen, Tim, Blinman, Prunella, Stockler, Martin R.

“…BACKGROUND: Little has been published regarding how doctors think and talk about prognosis and the potential benefits of adjuvant therapy. OBJECTIVE: We sought…”
Get full text

What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial by Lawrence, Nicola J., Martin, Andrew, Davis, Ian D., Troon, Simon, Sengupta, Shomik, Hovey, Elizabeth, Coskinas, Xanthi, Kaplan, Richard, Smith, Benjamin, Ritchie, Alastair, Meade, Angela, Eisen, Tim, Blinman, Prunella, Stockler, Martin R.

“…Background: Decisions about adjuvant therapy involve trade-offs between possible benefits and harms. Objective: We sought to determine the survival benefits…”
Get full text

Phase II trial of BNC105P as second-line chemotherapy for advanced malignant pleural mesothelioma (MPM): Australasian Lung Cancer Trials Group and NHMRC Clinical Trials Centre Collaboration by Nowak, Anna K., Brown, Chris, Millward, Michael, Hughes, Brett Gordon Maxwell, Bibby, David C., Kremmidiotis, Gabriel, Doolin, Elizabeth E., Mitchell, Paul, Pavlakis, Nick, Coskinas, Xanthi, Sebastian, Lucille T, Cummins, Michelle M, Boyer, Michael J., Parnis, Francis, Lavranos, Tina C., Stockler, Martin R.

“…Abstract only 7079^ Background: BNC105P is a tubulin polymerization inhibitor that acts as a Vascular Disrupting Agent (VDA), has direct cytotoxic effects, and…”
Get full text

Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial) by Smith, Michaella J, Gill, P. Grantley, Wetzig, Neil, Sourjina, Tatiana, Gebski, Val, Ung, Owen, Campbell, Ian, Kollias, James, Coskinas, Xanthi, Macphee, Avis, Young, Leonie, Simes, R. John, Stockler, Martin R

“…The RACS sentinel node biopsy versus axillary clearance (SNAC) trial compared sentinel-node-based management (SNBM) and axillary lymph-node dissection (ALND)…”
Get full text